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Background: An elevated plasma total homocysteine (tHcy) level is an independent
risk factor for vascular events. The aim of the present study was to investigate the
association between tHcy levels in the acute phase of cerebral infarction and functional
outcome among elderly patients.
Methods: Between October 2009 and December 2012, we recruited 594 elderly
patients (age > 75) with first-onset acute cerebral infarction who were consecutively
admitted to the Department of Neurology of Tianjin Huanhu Hospital, China. Levels of
tHcy and other biochemical values were measured within 24 h after admission. tHcy
values were classified according to quartiles (<9.94; 9.94 to <12.7; 12.7 to <16.8; and
≥16.8 µmol/L). We examined the relationship between tHcy levels at admission and
modified Rankin Scale scores (mRS) using univariate and multivariate analyses. Patients
were followed up at 3 months and 1 year after stroke.
Results: Within 3 months after stroke, 64 patients died, 37 had recurrent ischemic
stroke, and 22 were lost to follow-up; thus, 471 patients were reviewed and analyzed.
By the time of the 1-year follow-up, an additional 48 patients had died, 44 had recurrent
ischemic stroke, and 40 had been lost to follow-up; the remaining 339 patients were
thus reviewed and analyzed. Elevated tHcy levels were not associated with functional
outcome among elderly patients with acute cerebral infarction (p > 0.05). Only the
National Institutes of Health Stroke Scale score was associated with a poor outcome
after adjusting for confounders at 3 months and 1 year (adjusted odds ratio, 1.38; 95%
CI, 1.28–1.49; p < 0.01; adjusted odds ratio, 1.34; 95% CI, 1.25–1.44; p < 0.01,
respectively).
Conclusion: Among elderly patients with acute cerebral infarction, elevated tHcy at
admission was not a predictive factor of outcome at 3 months and 1 year after stroke
onset.
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INTRODUCTION
Stroke is the second most common cause of death and the leading
cause of disability worldwide, especially among aging patients
(Lloyd-Jones et al., 2010). An estimated two million strokes occur
each year in China, and the Chinese population is aging, with 200
million residents aged ≥65 years (Liu et al., 2011).
Some serum biomarkers, such as homocysteine (Hcy) have
a predictive value in evaluating vascular events (Boushey et al.,
1995; Eikelboom et al., 1999; Collaboration, 2002; Klerk et al.,
2002; Wald et al., 2002). Hcy is a sulfhydryl-containing amino
acid that is derived from the essential amino acid methionine,
which is found in animal sources of protein (Hankey and
Eikelboom, 1999).
A recent study shows that elevated tHcy levels could be
associated with poor outcomes after stroke onset in women, but
not in men (Zhong et al., 2016). However, little is known about
the relationship between elevated tHcy and functional outcome
among elderly patients with a cerebral infarction.
Therefore, the aim of the present study was to investigate the
association between tHcy levels in the acute phase of cerebral
infarction and functional outcome among elderly patients.
MATERIALS AND METHODS
The present study received the approval of the Ethics Committee
of Tianjin Huanhu Hospital, and all procedures were in
accordance with the ethical standards set forth by the committee.
Informed consent was obtained from all individual participants
included in the study. The present study is observational studies,
without giving extra intervention on the patients.
Patient Selection
We used a hospital-based registry of consecutive patients with
first-onset acute cerebral infarction from October 2009 to
December 2012. All patients were admitted into the Department
of Neurology of Tianjin Huanhu Hospital, which is a specialized
neurology hospital in Tianjin, China. Diagnosis of acute cerebral
infarction was made according to the criteria of the World
Health Organization (Schlegel et al., 2003). The inclusion criteria
included a first ischemic stroke within 7 days, which was
confirmed by imaging studies of the head (magnetic resonance
imaging or computed tomography). Exclusion criteria for the
present study were an age ≤75 years, B vitamin and/or folic acid
therapy within 2 weeks of hospital admission, renal failure, or an
unwillingness to participate.
Detailed baseline demographics and clinical characteristics
were collected and recorded during the patient hospitalization.
Patients or their authorized proxies were followed up at 3 months
and 1 year after stroke onset through either telephone or face-
to-face interviews. Follow-up results were immediately recorded
into the stroke database.
We retrospectively reviewed and extracted data from the
registry. Among 2,155 patients with acute cerebral infarction
who were admitted to the hospital within 7 days of stroke
onset, 1,561 patients who were aged ≤75 years were excluded
from the analysis. A total of 594 patients aged >75 years with
acute cerebral infarction were included in the study. Finally, 471
patients were followed up at 3 months, and 339 patients were
followed up at 1 year (Figure 1).
Demographic and Clinical
Characteristics
Baseline information and stroke risk factors for all patients were
collected within 24 h of admission. The baseline information
included age, sex, height, and weight data. Stroke risk factors
included a clinical medical history of hypertension, diabetes
mellitus, atrial fibrillation, dyslipidemia, or cerebral artery
stenosis. We also assessed patients’ modifiable lifestyle factors,
including current smoking status (≥1 cigarette per day for
1 year) and current alcohol drinker status (≥1 drink per week
for 1 year). Body mass index was measured according to body
weight and height, and obesity was defined as a body mass index
≥30 kg/m2.
The stroke subtypes were classified according to the Trial of
Org 10172 in Acute Stroke Treatment (TOAST) criteria, and
were defined as atherothrombotic, cardioembolic, lacunar, other
causes, and undetermined (Adams et al., 1993). The National
Institutes of Health Stroke Scale (NIHSS) was evaluated at
the time of admission. The modified Rankin Scale (mRS) was
evaluated at 3 months and 1 year after stroke onset.
Laboratory Methods
Blood biochemical variables were measured following a fast of
at least 8 h on the first day after admission. Levels of tHcy were
measured using nephelometric technology, which was conducted
on a BNII system (SIEMENS, Erlangen, Germany). Serum
high-sensitivity C-reaction protein (hsCRP) concentration was
measured using an immunoturbidimetric assay. Fasting glucose
was determined using the glucose oxidase method. All variables
were analyzed in a certified central laboratory.
Quartile classification is the most common statistical layering
method; therefore tHcy values were classified into four groups
according to quartiles (<9.94; 9.94 to <12.7; 12.7 to <16.8; and
≥16.8 µmol/L).
Study Outcome
To evaluate functional outcome in elderly patients, functional
impairment was graded using the mRS. A favorable outcome was
defined as an mRS score of 0–2 at 3 months and 1 year after stroke
onset. A poor outcome was defined as an mRS score of 3–5, which
indicates that patients cannot live independently.
Statistical Analysis
In the present study, categorical variables are reported as
counts and percentages, and continuous variables are reported
as median values or means ± standard deviations. Normality of
distribution was assessed with frequency histograms and normal
probability plots. The univariate associations between variables
of interest were evaluated using a Student’s t-test, Kruskal–
Wallis test, and chi-square test, as appropriate. Covariate-
adjusted associations between the variables of interest were
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FIGURE 1 | How chart of patient selection.
assessed using a logistic regression analyses. The selection
of the potentially confounding covariates was based on the
existing knowledge about their potential relationship with the
variable in focus. Two-tailed tests of significance were performed,
and p-values < 0.05 were considered statistically significant.
The software package SPSS version 21.0 was used to perform
statistical analyses.
RESULTS
Baseline Demographics and Clinical
Characteristics According to Quartiles of
tHcy Levels
Baseline demographics and clinical characteristics according to
quartiles of tHcy levels are listed in Table 1. A total of 594
elderly patients (323 men [54.4%]; median age, 78 years) were
included in the present study. The mean tHcy level of all elderly
patients was 15.61± 10.77 mmol/L (range, 2.42–105.00µmol/L);
a total of 437 (73.6%) patients had hypertension, 172 (29.0%) had
diabetes mellitus, 91 (15.3%) had atrial fibrillation, 125 (21.0%)
had dyslipidemia, and 130 (21.9%) had cerebral arterial stenosis.
Regarding the modifiable lifestyle factors, 123 (20.7%) patients
were current smokers, 36 (6.1%) were alcohol drinkers, and 101
(17.0%) were obese. Elderly patients with elevated tHcy levels
were more likely to be male than patients with lower tHcy
levels. Stroke subtypes were equally distributed among the Hcy
quartiles. There was no statistically significant difference among
the stratifications with regard to stroke severity and the mean
time from stroke onset (p= 0.693, p= 0.888, respectively).
Results at a 3-Month Follow-up
A total of 64 (10.8%) patients died within 3 months of
stroke onset. Among these patients, 17 patients (16 from
cerebral infarction and complications, 1 from acute myocardial
infarction) died during hospitalization, and 47 patients (36 from
cardio-cerebral vascular events and complications, 11 from other
causes) died during the first 3 months of follow-up. Thirty-
seven patients had recurrent ischemic stroke, and 22 patients
were lost to follow-up (Figure 1). At the 3-month follow-up,
471 patients responded by telephone or in-person interview
and were included in the analysis. There were 246 patients
with mRS scores of 0–2 and 225 patients with mRS scores of
3–5. Univariate analyses demonstrated that total cholesterol, low
density lipoprotein cholesterol, hsCRP, fasting blood glucose, and
NIHSS score were associated with a poor outcome; however, only
NIHSS score was associated with a poor outcome after adjusting
for confounders (adjusted odds ratio [OR], 1.38; 95% CI,
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TABLE 1 | Baseline characteristics of all patients according to quartiles of tHcy levels.
Q1 (<9.94), n = 150 Q2 (9.94–12.7), n = 149 Q3 (12.7–16.8), n = 147 Q4 (>16.8), n = 148 P
Age, year∗ 78 78 79 79 0.768
Male, n (%) 68 (45.3) 68 (45.3) 91 (61.9) 96 (64.9) 0.000
Hypertension, n (%) 111 (74.0) 106 (71.1) 102 (69.4) 118 (79.7) 0.197
DM, n (%) 49 (32.7) 53 (35.6) 36 (24.5) 34 (23.0) 0.043
AF, n (%) 30 (20.0) 22 (14.8) 23 (15.6) 16 (10.8) 0.179
Dyslipidemia, n (%) 42 (28.0) 28 (18.8) 25 (17.0) 30 (20.3) 0.097
CAS, n (%) 32 (21.3) 23 (15.4) 35 (26.9) 40 (27.0) 0.100
Smoking, n (%) 27 (18.0) 28 (18.8) 28 (19.0) 40 (27.0) 0.183
Alcohol drinker, n (%) 7 (4.7) 7 (4.7) 10 (6.8) 12 (8.1) 0.526
Obesity, n (%) 27 (18.0) 28 (18.8) 21 (14.3) 25 (16.9) 0.750
TOAST subtype 0.859
LA 73 (48.7) 82 (55.0) 77 (52.4) 85 (57.4)
CE 10 (6.7) 15 (10.1) 15 (10.2) 14 (9.5)
SA 47 (31.3) 32 (21.5) 36 (24.5) 32 (21.6)
OE 10 (6.7) 9 (6.0) 9 (6.1) 7 (4.7)
UE 10 (6.7) 11 (7.4) 10 (6.8) 10 (6.9)
CHO, mmol/L∗ 4.79 (1.29) 4.84 (1.53) 4.37 (1.32) 4.71 (1.21) 0.147
TG, mmol/L∗ 1.06 (0.62) 1.05 (0.75) 1.03 (0.77) 1.07 (0.75) 0.983
HDL-C, mmol/L∗ 1.01 (0.35) 1.04 (0.42) 1.02 (0.31) 0.98 (0.32) 0.599
LDL-C, mmol/L∗ 3.17 (1.20) 2.95 (1.12) 2.73 (1.05) 3.03 (1.08) 0.268
FG, mmol/L∗ 5.83 (2.93) 5.61 (2.30) 5.50 (2.18) 5.57 (1.53) 0.166
hsCRP, mg/L∗ 4.34 (15.72) 4.26 (8.31) 3.97 (12.25) 5.29 (15.36) 0.357
Hcy, µmol/L 8.75 (1.58) 11.30 (1.25) 14.50 (2.00) 22.40 (14.35) <0.001
NIHSS∗ 6.50 (10.75) 6.00 (9.00) 7.00 (11.00) 8.00 (9.00) 0.693
Time # 83.04 ± 50.94 80.38 ± 53.59 80.97 ± 49.87 84.65 ± 52.70 0.888
DM, diabetes mellitus; AF, atrial fibrillation; CAS, cerebral artery stenosis; CHO, cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol; FG, fasting glucose; hsCRP, high sensitivity C-reactive protein; Hcy, homocysteine. NIHSS, National Institutes of Health Stroke Scale.
Time represents hours from stroke onset.
∗Median (interquartile range); #Mean ± standard deviation.
1.28–1.49; p < 0.01). Total cholesterol, low-density lipoprotein
cholesterol, hsCRP, time from stroke onset, and fasting blood
glucose levels had no relationship with a poor outcome after
adjusting for confounders. There was no significant difference in
outcome among patients grouped by tHcy quartile at a 3-month
follow-up (Table 2).
Results at a 1-Year Follow-Up
Among the 471 patients available for follow-up at 3 months, 48
(10.2%) patients died, 44 (9.3%) patients had recurrent ischemic
stroke, and 40 (8.5%) patients were lost at a 1-year follow-
up at 1 year. Thirty-two patients died from cardio-cerebral
vascular events and complications, and 16 died from other causes
(Figure 1). A total of 339 patients responded by telephone or
in-person interview at 1 year and were included in the analysis.
There were 220 patients with mRS scores of 0–2, and 119 patients
with mRS scores of 3–5. Univariate analyses demonstrated that
atrial fibrillation, low-density lipoprotein cholesterol levels, and
NIHSS score were associated with a poor outcome; however, only
NIHSS score was associated with a poor outcome after adjusting
for confounders (adjusted odds ratio, 1.34; 95% CI, 1.25–1.44;
p < 0.01). Atrial fibrillation, time from stroke onset, and low-
density lipoprotein cholesterol levels had no relationship with a
poor outcome after adjusting for confounding variables. There
was no significant difference in outcome among patients grouped
by tHcy quartile at a 1-year follow-up (Table 2).
DISCUSSION
Some neurological scales, such as the NIHSS and mRS (Schlegel
et al., 2003; Wilson et al., 2005; Bruno et al., 2013; Kim et al.,
2013), can predict stroke patient outcomes. However, it is very
difficult to evaluate patient outcomes using scales when patients
suffer from apraxia, aphasia, or disorientation. In addition,
specific serum biomarkers also have predictive value in evaluating
stroke outcome (Yang et al., 2014; Yoo et al., 2014). Therefore, it
is important for clinicians to evaluate functional impairment and
predict patient outcome after ischemic stroke, as this would help
in determining early-stage treatment and rehabilitation methods.
Stroke severity is a well-known predictor of stroke outcome
(Veerbeek et al., 2011). Furthermore, the clinical predictive
validity of the NIHSS score has been shown in several
investigations (Schlegel et al., 2003; Kwah et al., 2013). Consistent
with other studies (Adams et al., 1999; Kwah et al., 2013), we
also found that initial NIHSS score was an independent predictor
(OR, 1.38; p < 0.01) of patient outcome at 3 months and (OR,
1.34; p< 0.01) 1 year after stroke.
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TABLE 2 | Predictors of poor functional outcome in elderly patients with
acute cerebral infarction.





CHO, mmol/L 1.25 (1.05–1.48) 0.01 0.81 (0.39–1.70) 0.58
LDL-C, mmol/L 1.37 (1.10–1.69) <0.01 1.74 (0.73–4.15) 0.70
hsCRP, mg/L 1.01 (1.00–1.02) 0.01 0.99 (0.98–1.01) 0.22
FG, mg/L 1.20 (1.08–1.35) <0.01 1.09 (0.94–1.27) 0.26
NIHSS 1.35 (1.27–1.43) <0.01 1.38 (1.28–1.48) <0.01∗
Time 1.00 (0.99–1.01) 0.26 0.99 (0.99–1.01) 0.78
tHcy∗
Q1 1 1
Q2 1.50 (0.90–2.50) 0.12 0.50 (0.17–1.50) 0.21
Q3 0.93 (0.55–1.56) 0.78 0.77 (0.28–2.10) 0.61
Q4 1.55 (0.77–2.15) 0.33 0.73 (0.27–1.94) 0.52
1 year
AF, (%) 2.04 (1.08–3.87) 0.03 0.96 (0.39–2.33) 0.92
LDL-C, mmol/L 1.26 (0.98–1.62) 0.08 1.26 (0.93–1.72) 0.14
NIHSS 1.34 (1.25–1.43) <0.01 1.34 (1.25–1.43) <0.01#
Time 1.00 (1.00–1.01) 0.068 1.00 (0.99–1.01) 0.28
tHcy#
Q1 1 1
Q2 1.05 (0.56–1.97) 0.87 1.16 (0.51–2.63) 0.73
Q3 0.85 (0.45–1.62) 0.63 1.25 (0.56–2.79) 0.59
Q4 1.07 (0.57–2.01) 0.83 0.98 (0.43–2.21) 0.96
CI indicates confidence interval; OR, odd ratio. Time represents hours from stroke
onset.
∗Adjusted for total cholesterol, low-density lipoprotein cholesterol level, high-
sensitivity C-reactive protein level, fasting glucose, NIHSS and time.
#Adjusted for atrial fibrillation, low-density lipoprotein cholesterol, NIHSS and time.
A previous study reported that serum Hcy is an independent
risk factor for stroke (Pang et al., 2014). The mechanisms
explaining the relationship between hyperhomocysteinemia and
stroke are not yet fully understood. Hyperhomocysteinemia
could induce changes in mRNA and protein expression of
CRP in vascular smooth muscle cells via the NMDAr-ROS-
ERK1/2/p38-NF-κB signal pathway (Kim et al., 2013). Moreover,
an increased serum Hcy level is an early atherosclerotic promoter.
Hyperhomocysteinemia causes cardiovascular disease through
not only the proliferation of vascular smooth muscle cells
but also the acceleration of endothelial dysfunction, platelet
coagulation, and cholesterol synthesis (Stuhlinger et al., 2001;
Ke et al., 2010; Shenoy et al., 2014). The findings on the
relationship between hyperhomocysteinemia and outcome after
stroke have been inconsistent (Del Ser et al., 2001; Faeh et al.,
2006). Moreover, trials investigating the effect of B vitamins,
which reduce tHcy levels, on endothelial function and outcome
of patients with cardiovascular disease have shown conflicting
results (Chambers et al., 2000; Title et al., 2000; Woo et al.,
2002; van Dijk et al., 2016). The heterogeneous methodologies
included in these studies may partially explain discrepancies in
the final results. For example, differences in time of evaluation,
age and sex of recruited patients, the localization of the stroke
area, outcome measures, and type of stroke may result in different
results.
There is debate about whether tHcy is a causative risk factor
in stroke or is merely a secondary marker of risk in survivors.
An evaluation of tHcy both before and after acute stroke would
help to answer this question. Given the difficulty in predicting
the onset of stroke, however, these data are unavailable. The
measurement of tHcy concentrations immediately after acute
stroke is necessary because an observation of elevated tHcy levels
at this time would be more suggestive of a causal association than
the occurrence of hyperhomocysteinemia in survivors sampled
at convalescent phases after stroke. Some studies report that
tHcy concentrations are not elevated after acute stroke, but
rise significantly at convalescent phases (Lindgren et al., 1995;
Meiklejohn et al., 2001). Our findings are in accordance with
the Lindgren et al. (1995) study; both studies recruited elderly
patients (median age, 78 vs.75 years) at the acute phase (mean
of 3 vs. 2 days after stroke onset), and tHcy concentration was
comparable (mean of 15.61 vs.13.4 µmol/L).
In the present study, both univariate and multivariate logistic
regression analyses indicated that an elevated Hcy level at
admission was not a predictive factor among elderly patients with
acute cerebral infarction. Similar findings reported that plasma
Hcy levels have no value as predictors of functional disability
in Asian patients with stroke (Mizrahi et al., 2005; Song et al.,
2009). However, the Mizrahi et al. (2005) study assessed patient
outcome with Function Independent Measure scores instead
of mRS scores, and those two studies recruited both younger
and elderly patients. One possible explanation for this finding
is that the association between Hcy level and stroke is not
causal among elderly patients. Alternatively, the harmful effects
of hyperhomocysteinemia could be masked by other vascular risk
factors, such as hypertension and diabetes. The patients included
in the present study were elderly, therefore the prevalence rates
of hypertension and diabetes were 74.9 and 29.5%, respectively,
which were much higher than rates than those reported in
other studies. However, there may be a causal link between
hyperhomocysteinemia and hypertension because elevated Hcy
levels may lead to hypertension through the induction of a
diastolic dysfunction of vessels and a reduction of vascular wall
flexibility. In addition, we failed to find any relationship between
the Hcy level and serum hsCRP level, indicating that elevated
Hcy does not lead to additional inflammatory responses among
elderly patients.
Some studies report that elevated Hcy levels can cause a more
severe stroke via multiple mechanisms, such as platelet activation,
inflammation, prothrombotic disorders, and fibrinolysis (Stamler
et al., 1993; Parnetti et al., 2004; Tay et al., 2006). However, in
accordance with the study by Perini et al. (2005), we found no
association between plasma tHcy and stroke severity, suggesting
that elevated tHcy is not associated with stroke severity in our
cohort of patients.
Another finding of the present study was that the percentage
of men was much higher in the two highest tHcy quartiles than
in the two lowest quartiles (65.7% vs. 44.5%). This result could
be explained by the fact that estrogen or estrogen associated with
progestin may have a positive role in decreasing cardiovascular
risk due to a significant reduction in Hcy levels (Lakryc et al.,
2015).
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There are a few limitations of the current study, as it
was retrospective and used data obtained from a single
hospital. Moreover, the present study was performed in
hyperhomocysteinemic elderly patients; therefore, our results
may not be representative of the general population. This
design may have resulted in an inevitable selection bias.
Regretfully, another limitation is the lack of data on repeated
measurements of Hcy levels during the follow-up period.
Future studies with larger patient populations are necessary to
assess the prognostic value of tHcy levels after acute cerebral
infarction.
CONCLUSION
In summary, in the present study, we observed that an elevated
tHcy level at admission was not a predictive factor of the outcome
at 3 months and 1 year after acute cerebral infarction among
elderly patients. These results indicate that it is necessary to treat
acute cerebral infarction on an individual basis in elderly patients,
especially when therapies to normalize plasma tHcy levels are
considered.
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